Session 7: Future of primary rectal cancer treatment
Role of external boost and brachytherapy in rectal cancer
Maaike Berbeé, the Netherlands
Challenges in rectal cancer surgery; which problems have to be solved?
Roel Hompes, the Netherlands
Locally recurrent rectal cancer; multimodality approach
Quentin Denost, France
Session 8: Systemic therapy in the metastatic setting – state of the art and future
Targeting RAS mutated tumors
Volker Heineman, Germany
Prognostic/predictive value of molecular and clinical factors: What makes the difference?
Teresa Macarulla, Spain
Feasibility and outcomes of a national expert panel of liver surgeons to determine secondary resectability in patients with initially unresectable colorectal liver metastases
Karen Bolhuis, the Netherlands
Session 9: Colorectal cancer and the immune system
What are the new drugs in the field of immunotherapy?
Guillem Argiles, Spain
What are the diagnostic tools and novel concepts of cancer evolution?
Jerome Galon, France
What are the effects that are interfering with local or current treatments?
Lunch & Poster viewing
CRC Group Meetings / trial Meetings / Consensus or guideline initiatives
Prospective Dutch CRC cohort (PLCRC): Nationwide infrastructure for colorectal cancer research in the Netherlands
Geraldine Vink, the Netherlands
Session 10: Genetics
Update: the genetic differential diagnosis of polyposis and CRC
Maartje Nielsen, the Netherlands
Predicting CRC risk: from tumor syndromes genes to polygenic risk scores
Richard Houlston, United Kingdom
Chemoprevention and vaccines for hereditary CRC
Matthias Kloor, Germany
Session 11: Curative treatment of metastases
Controversies in loco-regional therapy of peritoneal metastases: What is really needed?
Niels Kok, the Netherlands
Liver-directed therapies (Hepatic arterial infusion, SIRT): What to use when?
Bas Groot Koerkamp, the Natherlands
Spectrum of treatments for lung metastases: SBRT, RFA, resection or no local therapy at all?
Dirk Van Raemdonck, belgium
Closing and drinks